Cost-effectiveness study of controlled ovarian stimulation with recombinant FSH.

Retrospective study of cost-effectiveness and clinical outcomes in controlled ovarian stimulation with follitropin alpha and delta - Cost-effectiveness study of controlled ovarian stimulation with recombinant FSH.

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031230698

Enrollment

400

Registered

2024-03-13

Start date

2024-03-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility Infertility, assisted reproductive technology

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients receiving assisted reproductive technology (IVF/ICSI) using follitropin delta or follitropin alpha as FSH mono protocol COS for the first time and who have never received assisted reproductive technology before. (First ART patients) Patients covered by insurance up to age 42.

Exclusion criteria

Exclusion criteria: Patients who deviate from the package insert for follitropin delta and follitropin alpha (contraindications). Patients who received concomitant administration of hMG preparations, urine-derived FSH preparations, clomiphene, or letrozole in addition to follitropin delta or alpha.

Design outcomes

Primary

Measure	Time frame
Calculation of ICER for follitropin delta and follitropin alpha using cumulative pregnancy rate as an efficacy index.	—

Secondary

Measure	Time frame
ICER calculation of follitropin delta and follitropin alpha using the number of oocytes retrieved, number of fertilizations zygotes (2PN), and number of blastocysts as efficacy indicators.	—

Contacts

Public Contactmasato Kobanawa

nothing

masato.kobanawa@gmail.com+81-299-58-3185

Outcome results